PrimaryMarkets

VIEW OUR WEBINARS

SOFI Spritz - Australia’s Aperitivo
SOFI Spritz - Australia’s Aperitivo
View Recording

Deal Snapshot
Deal Snapshot
View Recording

Pre-IPO Trading with PrimaryMarkets
Pre-IPO Trading with PrimaryMarkets
View Recording

AIRR - Profile Video
AIRR - Profile Video
View Recording

Deal Snapshot
Deal Snapshot
View Recording

ASX Announcements  

2018

Date Announcement
21/11/2018 Change of Director's Interest Notice - LC
21/11/2018 Appendix 3B and 708A Notice
21/11/2018 Change of Director's Interest Notice - PH
13/11/2018 Results of Meeting
13/11/2018 AGM Presentation
13/11/2018 Imugene Advances to Phase 2 in Gastric Cancer Immuno-oncology Trial
09/11/2018 Imugene Received $1.85 million R&D Tax Incentive
30/10/2018 Appendix 4C - quarterly
22/10/2018 Change of Director's Interest Notice - AH
22/10/2018 Appendix 3B (Exercise of Options) and 708A Notice
09/10/2018 Notice of Annual General Meeting
08/10/2018 Change in Executive Remuneration
04/10/2018 European Society for Medical Oncology President joins Imugene Scientific Advisory Board
01/10/2018 Imugene appoints leading cancer researcher to Scientific Advisory Board
28/09/2018 Appendix 4G
21/09/2018 Imugene commences cGMP manufacture of PD-1 cancer vaccine
18/09/2018 Imugene appoints gastrointestinal cancer expert to Scientific Advisory Board
11/09/2018 Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
31/08/2018 Appendix 4E and Audited Financial Report
23/08/2018 Imugene appoints Dr Mark Marino Chief Medical Officer
27/07/2018 2018 Bioshares Presentation
23/07/2018 PD-1 cancer vaccine development update
07/06/2018 Capital Raising Presentation
07/06/2018 Prospectus
07/06/2018 Imugene to Raise A$20.1 million
07/06/2018 Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
05/06/2018 Trading Halt
28/03/2018 Leslie Chong Appointed as Managing Director
18/02/2018 Imugene arginine modulator demonstrates activity in melanoma cancer model
11/02/2018 Novel Anti-PD-1 Mimotope Vaccine Ready for Development
09/02/2018 Imugene hosts investigator meeting for gastric cancer clinical trial
07/02/2018 Cancer vaccine shows early promise in gastric cancer clinical trial
29/01/2018 Business Update – December Quarter Appendix 4C

 

2017

Date Announcement
04/12/2017 International Cancer Specialist Joins Imugene’s SAB
23/11/2017 IMUGENE RAISES $8.7 MILLION
23/11/2017 IMU - Prospectus
23/11/2017 IMU Capital Raising Presentation
23/11/2017 Entitlement Offer - notice to option holders
23/11/2017 Entitlement Offer - notice to ineligible shareholders
23/11/2017 Entitlement Offer – notice to eligible shareholders
24/10/2017 Imugene Limited to Present at Australia Biotech Invest 2017
16/10/2017 Expert briefing and Q&A 
11/10/2017 Imugene Receives $1.1 million in Research and Development Tax Refund
06/10/2017 Imugene Investor Presentation
31/08/2017 Imugene commences first patient dosing of HER-Vaxx
21/07/2017 Canadian patent granted for HER-Vaxx
17/07/2017 Investor Presentation July 2017
26/06/2017 Change of Address
30/03/2017 $1.35 million Options Underwritten
27/02/2017 Intellectual Property Strengthened Around Lead Clinical Drug HER-Vaxx
13/02/2017 Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research
09/01/2017 Presentation by Leslie Chong at 9th Annual Biotech Showcase, San Francisco 9 Jan 17
Become a Follower